Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Maloney · SciRah

Researcher profile · Semantic Scholar

D. Maloney

Share profile

D. Maloney — researcher profile on SciRah

h-index: 105
Works: 646
Citations: 45K

Most-cited papers

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
C. Jacobson, J. Chavez, A. Sehgal, B. William +19 more
2021The Lancet Oncology523 citations
Semantic Scholar
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
M. Kamdar, S. Solomon, J. Arnason, P. Johnston +17 more
2022The Lancet478 citations Open access
Semantic Scholar
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
C. Jacobson, B. Hunter, R. Redd, S. Rodig +23 more
2020Journal of Clinical Oncology295 citations Open access
Semantic Scholar
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.
J. Gauthier, Evandro D. Bezerra, A. Hirayama, Salvatore Fiorenza +21 more
2020Blood179 citations Open access
Semantic Scholar
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study
T. Siddiqi, D. Maloney, S. Kenderian, D. Brander +18 more
2023The Lancet151 citations Open access
Semantic Scholar
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
Krishna R. Juluri, Q. Wu, J. Voutsinas, Jue Hou +7 more
2021Blood Advances135 citations Open access
Semantic Scholar
Anakinra for refractory CRS or ICANS after CAR T-cell therapy
Nicolas Gazeau, Emily C. Liang, Q. Wu, J. Voutsinas +20 more
2023Transplantation and Cellular Therapy128 citations Open access
Semantic Scholar
Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
C. Jacobson, J. Chavez, A. Sehgal, B. William +21 more
2020110 citations Open access
Semantic Scholar
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
A. Cowan, M. Pont, Blythe Sather, C. Turtle +16 more
2023The Lancet Oncology86 citations Open access
Semantic Scholar
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies
Carla S. Walti, Elizabeth M. Krantz, J. Maalouf, J. Boonyaratanakornkit +14 more
2021JCI Insight85 citations Open access
Semantic Scholar
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.
S. Schuster, R. Maziarz, Elisha S. Rusch, Jun-Long Li +4 more
2020Blood Advances64 citations Open access
Semantic Scholar
Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
A. Hirayama, E. Kimble, J. H. Wright, Salvatore Fiorenza +19 more
2023Blood Advances57 citations Open access
Semantic Scholar
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
J. Gauthier, Nicolas Gazeau, A. Hirayama, J. Hill +18 more
2022Blood55 citations Open access
Semantic Scholar
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
D. Maloney, J. Kuruvilla, Fei-Fei Liu, A. Kostić +5 more
2021Journal of Hematology & Oncology53 citations Open access
Semantic Scholar
Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
J. Abramson, M. Palomba, L. Gordon, M. Lunning +13 more
2021Blood52 citations Open access
Semantic Scholar
Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
C. Jacobson, J. Chavez, A. Sehgal, B. William +16 more
202049 citations
Semantic Scholar
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study
Carla S. Walti, Andrea N. Loes, Kiel Shuey, Elizabeth M. Krantz +14 more
2021Journal for ImmunoTherapy of Cancer47 citations Open access
Semantic Scholar
Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.
R. Maziarz, S. Schuster, V. Romanov, Elisha S. Rusch +4 more
2020Blood Advances44 citations Open access
Semantic Scholar
Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
S. Neelapu, J. Chavez, A. Sehgal, N. Epperla +20 more
2021Blood37 citations Open access
Semantic Scholar
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
Emily C Liang, Aya Albittar, Jennifer J. Huang, A. Hirayama +12 more
2023Blood Advances35 citations Open access
Semantic Scholar
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
Jason P. Cooper, B. Storer, Noa Granot, B. Gyurkocza +31 more
2020Haematologica34 citations Open access
Semantic Scholar
Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
Donald L. Patrick, A. Powers, M. Jun, Yeonhee Kim +3 more
2021Blood Advances29 citations Open access
Semantic Scholar
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
J. Westin, C. Jacobson, J. Chavez, A. Sureda +16 more
2023Journal of Clinical Oncology27 citations
Semantic Scholar
Biology of Blood and Marrow Transplantation
Julia Ruark, Erin Mullane, Nancy Cleary, Ana Cordeiro +10 more
202024 citations
Semantic Scholar
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
G. Cartron, C. Fox, Fei-Fei Liu, A. Kostić +6 more
2022Experimental Hematology & Oncology21 citations Open access
Semantic Scholar
Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma
A. Cowan, M. Pont, Blythe Sather, C. Turtle +14 more
2021Blood20 citations Open access
Semantic Scholar
Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy
J. Hill, Erika S. Kiem, Atif Bhatti, Winnie Liu +11 more
2022American Journal of Transplantation19 citations Open access
Semantic Scholar
Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy
Nicolas Gazeau, P. Barba, G. Iacoboni, M. Kwon +17 more
2021Blood16 citations Open access
Semantic Scholar
Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
M. Shadman, Cecilia C. S. Yeung, M. Redman, Sang-Yun Lee +16 more
202016 citations Open access
Semantic Scholar
A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help
K. Curran, S. Nikiforow, C. Bachier, Y. Hsu +10 more
2023Blood Advances15 citations Open access
Semantic Scholar
Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma
T. Howell, L. Matza, M. Jun, Jacob Garcia +2 more
2022PharmacoEconomics - Open15 citations Open access
Semantic Scholar
Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study
L. Iovino, Q. Wu, J. Voutsinas, Lorena Panaite +12 more
2022Journal of Cellular and Molecular Medicine15 citations Open access
Semantic Scholar
Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
C. Bachier, J. Godwin, C. Andreadis, M. Palomba +13 more
202014 citations
Semantic Scholar
Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).
C. Jacobson, J. Chavez, A. Sehgal, B. William +16 more
202113 citations
Semantic Scholar
Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.
V. Chow, A. Gopal, J. Gauthier, Yolanda D. Tseng +3 more
2020Blood Advances12 citations Open access
Semantic Scholar
Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor–modified T-cell therapy
Michael A Gonzalez, Atif M Bhatti, K. Fitzpatrick, J. Boonyaratanakornkit +13 more
2022Blood Advances11 citations Open access
Semantic Scholar
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
C. Ujjani, Catherine Lai, L. Leslie, P. Ramzi +21 more
2020Blood11 citations
Semantic Scholar
Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product
C. Jacobson, F. Locke, D. Miklos, J. Vose +13 more
202010 citations
Semantic Scholar
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
D. Maloney, J. Kuruvilla, C. Fox, G. Cartron +5 more
2020Blood10 citations Open access
Semantic Scholar
Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5
J. Chavez, C. Jacobson, A. Sehgal, S. Neelapu +8 more
202010 citations Open access
Semantic Scholar
Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL
M. Shadman, Cecilia C. S. Yeung, M. Redman, Sang-Yun Lee +18 more
2021Blood9 citations Open access
Semantic Scholar
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma
S. Tuazon, R. Cassaday, T. Gooley, B. Sandmaier +14 more
2020Biology of Blood and Marrow Transplantation8 citations Open access
Semantic Scholar
Patient-Reported Outcomes at Time of CAR-T Cell Therapy
Erin Mullane, Taylor Jones, J. Voutsinas, Q. Wu +4 more
20208 citations Open access
Semantic Scholar
Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Alexandre Vinaud Hirayama, Salvatore Fiorenza, J. Gauthier, J. Voutsinas +15 more
2022Blood6 citations Open access
Semantic Scholar
Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
M. Shadman, D. Maloney
2021Hematology/Oncology Clinics of North America6 citations
Semantic Scholar
CMV and HHV-6 after Chimeric Antigen Receptor (CAR)-T-Cell Immunotherapy for B-Cell Malignancies: A Prospective Study
E. Kampouri, S. Ibrahimi, Jessica Hecht, Jacob Keane-Candib +10 more
2023Transplantation and Cellular Therapy5 citations Open access
Semantic Scholar
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
M. Shadman, C. Yeung, M. Redman, S. Y. Lee +21 more
2023Hematological Oncology5 citations Open access
Semantic Scholar
Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*).
J. Specht, D. Maloney, Cecilia C. S. Yeung, V. Wu +1 more
20215 citations
Semantic Scholar
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma
V. Chow, R. Cassaday, T. Gooley, Stephen D. Smith +9 more
2021Blood Advances5 citations Open access
Semantic Scholar
Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5.
J. Chavez, C. Jacobson, A. Sehgal, S. Neelapu +8 more
20215 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Turtle×19
Invite
C. Turtle — researcher profile on SciRah
J. Gauthier×17
Invite
J. Gauthier — researcher profile on SciRah
D. Green×16
Invite
D. Green — researcher profile on SciRah
B. Till×12
Invite
B. Till — researcher profile on SciRah

×10

Invite

C. Jacobson — researcher profile on SciRah

Invite

A. Gopal — researcher profile on SciRah

Invite

M. Shadman — researcher profile on SciRah

Invite

A. Sehgal — researcher profile on SciRah

Invite

A. Hirayama — researcher profile on SciRah

Invite

A. Chapuis — researcher profile on SciRah

Invite

A. Cowan — researcher profile on SciRah

Invite

J. Chavez — researcher profile on SciRah